AbstractThe present study demonstrates that blood samples can be used as a source of miRNA identification associated to Parkinson's disease (PD). A set of six differentially expressed microRNAs were identified. They form two groups according to their expression profile in control, non-treated, early-onset and treated Parkinson's disease subjects. While miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients. This study is innovative in contributing to the development of effective PD biomarkers
none9siBACKGROUND: Research on microRNAs (miRNAs) is becoming an increasingly attractive field, as t...
Abstract Blood circulating microRNAs (miRNAs) are proposed to be promising biomarkers for many neuro...
Parkinson’s disease (PD) is a neurodegenerative synucleinopathy that has a not yet fully understood ...
AbstractThe present study demonstrates that blood samples can be used as a source of miRNA identific...
Background. Parkinson's disease (PD) is a progressive neurodegenerative disorder which may be misdia...
Abstract Background Blood-based test for predicting disease progression and early diagnosis of Parki...
Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disease characterized by ...
Parkinson’s disease (PD) is characterized by the progressive loss of dopaminergic neurons in the sub...
Parkinson's disease (PD) is the second most common neurodegenerative disease. One of the major chall...
Parkinson’s disease (PD) is the second most common neurodegenerative disorder worldwide. Its main ne...
Parkinson's disease (PD) is an important disabling age‑related disorder and is the second most commo...
Parkinson’s disease (PD) is a progressive neurological disorder that affects 1% of the population ov...
Parkinsonâs disease (PD) diagnosis is based on the assessment of motor symptoms, which manifest when...
As current clinical diagnostic protocols for Parkinson's disease (PD) may be prone to inaccuracies t...
Parkinson’s Disease (PD) is a chronic, progressive neurodegenerative disease characterised by both m...
none9siBACKGROUND: Research on microRNAs (miRNAs) is becoming an increasingly attractive field, as t...
Abstract Blood circulating microRNAs (miRNAs) are proposed to be promising biomarkers for many neuro...
Parkinson’s disease (PD) is a neurodegenerative synucleinopathy that has a not yet fully understood ...
AbstractThe present study demonstrates that blood samples can be used as a source of miRNA identific...
Background. Parkinson's disease (PD) is a progressive neurodegenerative disorder which may be misdia...
Abstract Background Blood-based test for predicting disease progression and early diagnosis of Parki...
Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disease characterized by ...
Parkinson’s disease (PD) is characterized by the progressive loss of dopaminergic neurons in the sub...
Parkinson's disease (PD) is the second most common neurodegenerative disease. One of the major chall...
Parkinson’s disease (PD) is the second most common neurodegenerative disorder worldwide. Its main ne...
Parkinson's disease (PD) is an important disabling age‑related disorder and is the second most commo...
Parkinson’s disease (PD) is a progressive neurological disorder that affects 1% of the population ov...
Parkinsonâs disease (PD) diagnosis is based on the assessment of motor symptoms, which manifest when...
As current clinical diagnostic protocols for Parkinson's disease (PD) may be prone to inaccuracies t...
Parkinson’s Disease (PD) is a chronic, progressive neurodegenerative disease characterised by both m...
none9siBACKGROUND: Research on microRNAs (miRNAs) is becoming an increasingly attractive field, as t...
Abstract Blood circulating microRNAs (miRNAs) are proposed to be promising biomarkers for many neuro...
Parkinson’s disease (PD) is a neurodegenerative synucleinopathy that has a not yet fully understood ...